Janux Therapeutics, Inc. (JANX) — Financial statements
Income statement, balance sheet, and cash flow for Janux Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 10↓5.6% | 11↑31.0% | 8↓6.1% | 9↑136.8% | 4 | |
| Cost of Revenue | 2↓1.5% | 2↑5.4% | 2↑132.5% | 0.84 | 0.00 | |
| Gross Profit | 8↓6.5% | 9↑39.2% | 6↓21.1% | 8↑113.7% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 126↑84.1% | 68↑24.5% | 55↑2.8% | 53↑103.7% | 26 | |
| General & Administrative Expenses | 42↑1.8% | 41↑57.0% | 26↑17.4% | 22↑115.5% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 42↑1.8% | 41↑57.0% | 26↑17.4% | 22↑115.5% | 10 | |
| Other Expenses | -2↑1.5% | -2↓5.4% | -2↓132.5% | -0.84 | 0.00 | |
| Operating Expenses | 166↑54.3% | 107↑35.7% | 79↑5.7% | 75↑104.7% | 37 | |
| Total Costs & Expenses | 168↑53.2% | 109↑35.0% | 81↑7.1% | 76↑107.0% | 37 | |
| Operating Results | ||||||
| Operating Income | -158↓59.5% | -99↓35.4% | -73↓8.8% | -67↓103.7% | -33 | |
| Depreciation & Amortization | 2↓1.5% | 2↑5.4% | 2↑132.5% | 0.84↑644.2% | 0.11 | |
| EBITDA | -112↓15.3% | -97↓36.3% | -71↓7.2% | -66↓101.9% | -33 | |
| EBIT | -114↓15.0% | -99↓35.4% | -73↓8.8% | -67↓103.7% | -33 | |
| Interest & Other Income | ||||||
| Net Interest Income | 44↑47.5% | 30↑103.3% | 15↑264.2% | 4↑1468.9% | 0.26 | |
| Interest Income | 44↑47.5% | 30↑103.3% | 15↑264.2% | 4↑1468.9% | 0.26 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 44↑47.5% | 30↑103.3% | 15↑264.2% | 4↑1468.9% | 0.26 | |
| Income Before Tax | -114↓64.7% | -69↓18.4% | -58↑7.6% | -63↓93.0% | -33 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -114↓64.7% | -69↓18.4% | -58↑7.6% | -63↓93.0% | -33 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -114↓64.7% | -69↓18.4% | -58↑7.6% | -63↓93.0% | -33 | |
| Bottom-Line Net Income | -114↓64.7% | -69↓18.4% | -58↑7.6% | -63↓93.0% | -33 | |
| EPS (Basic) | -1.83↓43.0% | -1.28↑3.0% | -1.32↑13.2% | -1.52↓92.4% | -0.79 | |
| EPS (Diluted) | -1.83↓43.0% | -1.28↑3.0% | -1.32↑13.2% | -1.52↓92.4% | -0.79 | |
| Weighted Average Shares | 62↑15.3% | 54↑22.1% | 44↑6.1% | 41↑0.5% | 41 | |
| Weighted Average Diluted Shares | 62↑15.3% | 54↑22.1% | 44↑6.1% | 41↑0.5% | 41 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.